Source: Annual Congress 2008 - Exacerbations of chronic respiratory disease – state of the art
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Rosenfeld (Seattle, Wa, United States of America). The concept of cystic fibrosis pulmonary exacerbation in clinical medicine and as a trial end-point. Annual Congress 2008 - Exacerbations of chronic respiratory disease – state of the art

Member's Comments

No comment yet.

Related content which might interest you: Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice Source: International Congress 2015 – Treatment of IPF Year: 2015 Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences Source: Eur Respir Rev 2015; 24: 420-427 Year: 2015 The experience of patients with cystic fibrosis during pulmonary exacerbations: a mixed-method study Source: International Congress 2017 – Nursing practice across respiratory care pathways Year: 2017 A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials Source: Eur Respir J 2015; 46: 243-249 Year: 2015 Doxycycline improves clinical outcomes during cystic fibrosis exacerbations Source: Eur Respir J , 49 (4)  1601102; DOI: 10.1183/13993003.01102-2016 Year: 2017 Clinical response to elexacaftor/tezacaftor/ivacaftor for cystic fibrosis patients in a compassionate use setting Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020 Differences in clinical features and biomarkers of subsequent acute cystic fibrosis pulmonary exacerbations - Analysing exacerbations as separate entities Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis Source: Eur Respir Rev 2015; 24: 58-64 Year: 2015 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis Source: Eur Respir Rev 2012; 21: 48-56 Year: 2012 Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry Source: Eur Respir J 2015; 46: 186-196 Year: 2015 Diagnosis of idiopathic pulmonary fibrosis: from guidelines to clinical practice Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease Year: 2009 Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis Source: Eur Respir J, 54 (6) 1901188; 10.1183/13993003.01188-2019 Year: 2019 Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research Source: Eur Respir J, 49 (6) 1700051; 10.1183/13993003.00051-2017 Year: 2017 A global perspective on acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF): results from an international survey Source: International Congress 2018 – Clinical news in idiopathic interstitial pneumonias Year: 2018 The effectiveness of pulmonary rehabilitation in patients diagnosed with interstitial pulmonary fibrosis Source: Virtual Congress 2020 – The multiple facets of pulmonary rehabilitation and chronic respiratory care Year: 2020 The INPULSIS trials of idiopathic pulmonary fibrosis treatment: explaining further discrepancies on exacerbations Source: Eur Respir J 2016; 47: 344-345 Year: 2016 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 End-points and biomarkers for clinical trials in cystic fibrosis Source: Eur Respir Monogr 2014; 64: 104-115 Year: 2014